FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Lightning Round: Priceline.com, Citigroup, Transocean and More
- Lightning Round OT: STEC, ICICI Bank and More
- Herbalife Vs. Hedge Funds
- Cramer Jeers J&J, Applauds Abbott
- Cramer: In This Relay-Race Market, Who Gets Baton Next?
- Cramer's Trade on Status-Conscious Consumers
- Mad Mail: Buy the Berkshire Hathaway Split?
- Lightning Round: American Express, McDonald's, Frontline and More
- Lightning Round OT: Ciena, Kinder Morgan Energy and More
- Don’t Pay Up for This Trade-Down Retailer
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
On Wednesday, Allscripts-Misys Healthcare Solutions surprised Wall Street by pre-announcing better-than-expected fourth-quarter and fiscal-year 2009 earnings. The company, known for its medical-records efficiency software, said its orders for the quarter would clock in at $103 million, a 26% jump year-over-year.
Typically, such a statement would give investors reason for cheer, but it wasn’t long before analysts voiced their doubts about Allscripts [MDRX
Loading...
()
]. Deutsche Bank on the same day issued a report saying, “It is tough to discern the actual performance of the company,” and therefore the stock should be sold.
Allscripts CEO Glenn Tullman shot right back on Friday’s Mad Money, telling Cramer that the company’s performance is quite “easy” to discern.
In fact, Tullman said, “we’re just getting started.”
He offered some numbers to back his case: There are 163,000 small-sized physician offices in the US, those with between one and three doctors, that still need to purchase Allscripts’ software. That amounts to about $1.5 billion in that segment of the market alone.
“We’ve got tons of opportunity,” the CEO said. “This market is heating up, and we’re ready for it.”
Tullman and Cramer discussed the company’s new distribution network, the coming impact of President Obama’s stimulus and how Allscripts is “the Bloomberg for health care.” Watch the video for that and find out why Cramer said this stock is “still a moneymaker.”
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes